Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Analysts
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) has received a consensus recommendation of “Hold” from the ten brokerages that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) has received a consensus recommendation of “Hold” from the ten brokerages that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective […]
